Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Advance Medical Research
2525
mi
from 98109
Saint Petersburg, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Advance Medical Research
2525
mi
from 98109
Saint Petersburg, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
KAMP Medical Research
1884
mi
from 98109
Natchitoches, LA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
KAMP Medical Research
1884
mi
from 98109
Natchitoches, LA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
CentraCare Heart & Vascular Center
1337
mi
from 98109
Saint Cloud, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
CentraCare Heart & Vascular Center
1337
mi
from 98109
Saint Cloud, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
HealthEast Medical Research Institute
1399
mi
from 98109
Saint Paul, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
HealthEast Medical Research Institute
1399
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
HealthEast St. Joseph's Hospital Pharmacy
1399
mi
from 98109
Saint Paul, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
HealthEast St. Joseph's Hospital Pharmacy
1399
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Mercy Research
1708
mi
from 98109
Saint Louis, MO
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Mercy Research
1708
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Manhattan Medical Research Practice PLLC
2402
mi
from 98109
New York, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Manhattan Medical Research Practice PLLC
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Amh/Feasterville Family Health Care Center
2375
mi
from 98109
Feasterville-Trevose, PA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Amh/Feasterville Family Health Care Center
2375
mi
from 98109
Feasterville-Trevose, PA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Arkansas Heart Hospital/Clinic
1776
mi
from 98109
Little Rock, AR
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Arkansas Heart Hospital/Clinic
1776
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research of Miami (ACROM) International
2731
mi
from 98109
Miami, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research of Miami (ACROM) International
2731
mi
from 98109
Miami, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
BWell Research Center
2731
mi
from 98109
Miami, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
BWell Research Center
2731
mi
from 98109
Miami, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
BayCare Medical Group
2501
mi
from 98109
New Port Richey, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
BayCare Medical Group
2501
mi
from 98109
New Port Richey, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Dr. Jeffrey Greiff MD, Office Of
2712
mi
from 98109
Plantation, FL
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Dr. Jeffrey Greiff MD, Office Of
2712
mi
from 98109
Plantation, FL
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Elite Clinial Trials, LLLP
572
mi
from 98109
Blackfoot, ID
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Elite Clinial Trials, LLLP
572
mi
from 98109
Blackfoot, ID
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage
1370
mi
from 98109
Council Bluffs, IA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage
1370
mi
from 98109
Council Bluffs, IA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room
1411
mi
from 98109
Duluth, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
St. Mary's Medical Center (Primary Practice Site)
1411
mi
from 98109
Duluth, MN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
St. Mary's Medical Center (Primary Practice Site)
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Cardiac and Endovascular Associates
2389
mi
from 98109
Ridgewood, NJ
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Cardiac and Endovascular Associates
2389
mi
from 98109
Ridgewood, NJ
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Scott Research, Inc.
2415
mi
from 98109
Laurelton, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Scott Research, Inc.
2415
mi
from 98109
Laurelton, NY
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Premier Health Specialists, Inc (dba Dayton Heart Center)
1957
mi
from 98109
Dayton, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Premier Health Specialists, Inc (dba Dayton Heart Center)
1957
mi
from 98109
Dayton, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
North Ohio Heart Center (Administrative Only)
2006
mi
from 98109
Elyria, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
North Ohio Heart Center (Administrative Only)
2006
mi
from 98109
Elyria, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
North Ohio Heart Center
2005
mi
from 98109
Elyria, OH
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
North Ohio Heart Center
2005
mi
from 98109
Elyria, OH
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
IP + Dry ice deliveries Sugar Lakes Family Practice
1888
mi
from 98109
Sugar Land, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
IP + Dry ice deliveries Sugar Lakes Family Practice
1888
mi
from 98109
Sugar Land, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Northwest Houston Heart Center
1863
mi
from 98109
Tomball, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Northwest Houston Heart Center
1863
mi
from 98109
Tomball, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Admin & Storage only:Northwest Heart Center
1863
mi
from 98109
Tomball, TX
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Admin & Storage only:Northwest Heart Center
1863
mi
from 98109
Tomball, TX
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC
2322
mi
from 98109
Washington,
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
Women's & Family Care, LLC D.B.A GTC Research
1495
mi
from 98109
Shawnee Mission, KA
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
Women's & Family Care, LLC D.B.A GTC Research
1495
mi
from 98109
Shawnee Mission, KA
Click here to add this to my saved trials
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated:  12/31/1969
NYU Hudson Valley Cardiology
2390
mi
from 98109
Cortlandt Manor, NY
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Status: Enrolling
Updated: 12/31/1969
NYU Hudson Valley Cardiology
2390
mi
from 98109
Cortlandt Manor, NY
Click here to add this to my saved trials
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2485
mi
from 98109
Boston, MA
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Status: Enrolling
Updated:  12/31/1969
David Grant USAF Medical Center
647
mi
from 98109
Travis Air Force Base, CA
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service
Status: Enrolling
Updated: 12/31/1969
David Grant USAF Medical Center
647
mi
from 98109
Travis Air Force Base, CA
Click here to add this to my saved trials
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated:  12/31/1969
Visiting Nurse Service of New York
2401
mi
from 98109
New York, NY
Center for Stroke Disparities Solution - Community Transitions Intervention
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)
Status: Enrolling
Updated: 12/31/1969
Visiting Nurse Service of New York
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Main
2020
mi
from 98109
Cleveland, OH
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Main
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Heart Hospital
1128
mi
from 98109
Mesa, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Heart Hospital
1128
mi
from 98109
Mesa, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan
1116
mi
from 98109
Phoenix, AZ
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Torrance Memorial Medical Center
977
mi
from 98109
Torrance, CA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Torrance Memorial Medical Center
977
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
1713
mi
from 98109
Elk Grove Village, IL
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
1713
mi
from 98109
Elk Grove Village, IL
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Boone Hospital Center
1614
mi
from 98109
Columbia, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Boone Hospital Center
1614
mi
from 98109
Columbia, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Hospital, Kansas City
1504
mi
from 98109
Kansas City, MO
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Hospital, Kansas City
1504
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Presbyterian Health System Hospital
1184
mi
from 98109
Albuquerque, NM
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Presbyterian Health System Hospital
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Peace Health Sacred Heart River Bend Medical Center
250
mi
from 98109
Springfield, OR
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Peace Health Sacred Heart River Bend Medical Center
250
mi
from 98109
Springfield, OR
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
York Hospital
2300
mi
from 98109
York, PA
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
York Hospital
2300
mi
from 98109
York, PA
Click here to add this to my saved trials
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
2401
mi
from 98109
New York, NY
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Point of Care (POC) Biomarkers of Ischemia
Point of Care (POC) Biomarkers of Ischemia
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealtlh University Health Systems
2350
mi
from 98109
Richmond, VA
Point of Care (POC) Biomarkers of Ischemia
Point of Care (POC) Biomarkers of Ischemia
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealtlh University Health Systems
2350
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
Advanced Cardiovascular, LLC
2142
mi
from 98109
Alexander City, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
Advanced Cardiovascular, LLC
2142
mi
from 98109
Alexander City, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
North Alabama Research Center
2038
mi
from 98109
Athens, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
North Alabama Research Center
2038
mi
from 98109
Athens, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
UAB Medical Center
2072
mi
from 98109
Birmingham, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
UAB Medical Center
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated:  12/31/1969
Mobile Heart Specialists, PC
2139
mi
from 98109
Mobile, AL
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Status: Enrolling
Updated: 12/31/1969
Mobile Heart Specialists, PC
2139
mi
from 98109
Mobile, AL
Click here to add this to my saved trials